Media headlines about The Cooper Companies (NYSE:COO) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. The Cooper Companies earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 46.7932366903716 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
Get The Cooper Companies alerts:
Homeownership Is Dead. The Future Lies in Public Housing. (inthesetimes.com) Form 4 COOPER COMPANIES INC For: May 01 Filed by: White Albert G III (streetinsider.com) Form 4 COOPER COMPANIES INC For: May 01 Filed by: Andrews Brian G (streetinsider.com) North Carolina Medicaid Scandal Broadens on Dem. Gov. Coopers Watch (spectator.org) Head to Head Contrast: STAAR Surgical (STAA) and The Cooper Companies (COO) (americanbankingnews.com)
A number of research firms recently commented on COO. Goldman Sachs began coverage on shares of The Cooper Companies in a research note on Wednesday, April 4th. They issued a “neutral” rating and a $231.00 price objective for the company. Zacks Investment Research lowered shares of The Cooper Companies from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. TheStreet lowered shares of The Cooper Companies from a “b” rating to a “c” rating in a research note on Thursday, March 8th. Oppenheimer set a $265.00 price objective on shares of The Cooper Companies and gave the stock a “hold” rating in a research note on Friday, March 9th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $280.00 price objective (up previously from $277.00) on shares of The Cooper Companies in a research note on Friday, March 9th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The Cooper Companies currently has an average rating of “Hold” and a consensus price target of $264.18.
Shares of NYSE:COO traded up $1.28 during trading on Friday, reaching $226.56. 216,442 shares of the company traded hands, compared to its average volume of 364,722. The firm has a market capitalization of $11,043.54, a P/E ratio of 23.36, a price-to-earnings-growth ratio of 1.77 and a beta of 0.62. The Cooper Companies has a 1-year low of $204.27 and a 1-year high of $260.26. The company has a quick ratio of 1.61, a current ratio of 2.83 and a debt-to-equity ratio of 0.75.
The Cooper Companies (NYSE:COO) last issued its earnings results on Thursday, March 8th. The medical device company reported $2.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.28. The company had revenue of $590.00 million during the quarter, compared to analyst estimates of $583.07 million. The Cooper Companies had a net margin of 7.83% and a return on equity of 16.90%. The company’s revenue for the quarter was up 18.2% on a year-over-year basis. During the same quarter last year, the business posted $1.93 EPS. equities research analysts expect that The Cooper Companies will post 11.82 earnings per share for the current fiscal year.
In other The Cooper Companies news, EVP Carol R. Kaufman sold 13,362 shares of The Cooper Companies stock in a transaction on Monday, March 12th. The shares were sold at an average price of $243.88, for a total transaction of $3,258,724.56. Following the completion of the sale, the executive vice president now owns 59,305 shares of the company’s stock, valued at approximately $14,463,303.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert S. Weiss sold 36,769 shares of The Cooper Companies stock in a transaction on Monday, March 12th. The shares were sold at an average price of $242.35, for a total transaction of $8,910,967.15. Following the sale, the chief executive officer now directly owns 135,936 shares of the company’s stock, valued at approximately $32,944,089.60. The disclosure for this sale can be found here. Insiders have sold a total of 51,846 shares of company stock valued at $12,549,839 in the last three months. Company insiders own 1.60% of the company’s stock.
About The Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.